Bibliography
- Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch Neurol 2002;59:1937-43
- Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol 2005;62:241-8
- Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Lancet 2005;365:947-54
- Youdim MBH, Gross A, Finberg JP. Rasagiline [N-propargyl-1R (+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 2001;132:500-6
- Chen JJ, Swope DM, Dashtipour K. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease. Clin Therapeutics 2007;9:1825-49
- Lew MF, Hauser RA, Hurtig HI, et al. Long-term efficacy of rasagiline in early Parkinson‘s disease. Int J Neurosci 2010;120:404-8
- Hauser R, Silver D, Choudhry A, Isaacson S. A placebo controlled, randomized, double-blind study to assess the safety and clinical benefit of rasagiline as an add-on therapy to dopamine agonist monotherapy in early Parkinson's disease (PD): The ANDANTE study. Poster P006 Presented at the 65th AAN-Meeting; 16-23 March 2013; San Diego
- Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 2009;361:1268-78
- Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10:415-23
- Jost WH, Klasser M, Reichmann H. Rasagilin im klinischen Alltag. Fortschr Neurol Psych 2008;76:594-9
- Hanagasi HA, Gurvit H, Unsalan P, et al. The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: a randomized, double-blind, placebo-controlled, multicenter study. Mov Disord 2011;26:1851-8
- Tolosa E, Stern MB. Efficacy, safety and tolerability of rasagiline as adjunctive therapy in elderly patients with Parkinson's disease. Eur J Neurol 2012;19:258-64
- Goetz CG, Schwid SR, Eberly SW, et al. Safety of rasagiline in elderly patients with Parkinson disease. Neurology 2006;66:1427-9
- Parkinson Study Group. DATATOP: a multicenter controlled trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60
- Jost WH, Friede M, Schnitker J. Indirect meta-analysis of randomised placebo-controlled clinical trials on rasagiline and selegiline in the symptomatic treatment of Parkinson's disease. Basal Ganglia 2012;2:S17-26